Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of modafinil in the treatment of cocaine addicts

A technology for cocaine and addiction, applied in the direction of medical preparations containing active ingredients, organic active ingredients, pill delivery, etc., can solve the problem of continuous effect beyond the patient

Inactive Publication Date: 2014-11-19
DEBREGEAS & ASSOCIES PHARMA
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] The problem with the commercial forms currently available is that the effects last far beyond what patients expect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of modafinil in the treatment of cocaine addicts
  • Use of modafinil in the treatment of cocaine addicts
  • Use of modafinil in the treatment of cocaine addicts

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0030] It has been presented that modafinil in CO 2 has acceptable solubility.

[0031] The next step consists of spraying the dissolved active ingredient on an inert carrier and then investigating the particle size of the obtained granules and the crystalline form of the same granules.

[0032] First, different experiments were carried out using anhydrous lactose as an inert carrier.

[0033] Then modify the different parameters:

[0034] changing the inert carrier (mannitol instead of anhydrous lactose),

[0035] Increase loading level to 30% active ingredient loading,

[0036] Using S modafinil,

[0037] In addition to CO 2 external supercritical solvents.

[0038] Trials using S modafinil and mannitol are summarized in the table below.

[0039]

[0040] The previously obtained formulation was formulated in order to obtain tablets of S modafinil at a dose of 2 mg for administration to rats during pharmacokinetic studies.

[0041] The method used is as follows:

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to the use of modafinil in cocaine addiction. The modafinil used is the dextrorotatory enantiomer thereof (modafinil S), having a very rapid release time of less than 1 hour, preferably 15-30 minutes, and very reduced wakefulness-promoting effects of less than 4 hours, preferably less than 2 hours. Said modafinil is to be taken in the form of a pharmaceutical composition via oral administration, each unit dose comprising 25-200 mg, preferably 50-100 mg, of modafinil S. The invention further relates to the use of said pharmaceutical composition as a substitution treatment for cocaine addicts.

Description

technical field [0001] Modafinil is 2-[(diphenylmethyl)sulfinyl]acetamide, its molecular formula is C15H15NO2S, and its structural formula is: [0002] Background technique [0003] Currently, cocaine use is the cause of many medical diseases and psychiatric complications such as addiction. Thus, cocaine addiction is a serious and growing public health problem. In the United States, it was reported that more than 200,000 had to receive emergency care in 2002 due to subsequent medical or psychiatric problems from cocaine use. Today, many molecules are available to treat cocaine addiction. In fact, cocaine's mode of action at the brain level involves at least three neurotransmitters: GABA (gamma-aminobutyric acid), glutamate, and DA (dopamine). Thus, various active molecules acting on these mediators have been effectively studied in humans. These molecules are baclofene, topiramate, modafinil, disulfiram ([BH Herman, A. Elkashef, F. Vocci-Medications for the treatment o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/16A61K9/20A61K9/48A61K31/165A61P25/36
CPCA61K9/2009A61K9/4866A61K9/4858A61K9/2027A61K9/2018A61K31/165A61P25/00A61P25/30A61P25/36A61K9/4825
Inventor 帕斯卡·祖普利菲利浦·维维特
Owner DEBREGEAS & ASSOCIES PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com